{"id":544891,"date":"2021-05-26T18:16:01","date_gmt":"2021-05-26T18:16:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=544891"},"modified":"2021-05-26T18:16:01","modified_gmt":"2021-05-26T18:16:01","slug":"wet-agerelated-macular-degeneration-wet-amd-market-analysis-market-size-trends-epidemiology-leading-companies-and-therapies-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/wet-agerelated-macular-degeneration-wet-amd-market-analysis-market-size-trends-epidemiology-leading-companies-and-therapies-delveinsight_544891.html","title":{"rendered":"Wet Age-related Macular Degeneration (wet AMD) Market Analysis, Market Size, Trends, Epidemiology, Leading Companies And Therapies | DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1622005922.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Wet Age-related Macular Degeneration (wet AMD) Market Analysis, Market Size, Trends, Epidemiology, Leading Companies And Therapies | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1622005922.png\" alt=\"Wet Age-related Macular Degeneration (wet AMD) Market Analysis, Market Size, Trends, Epidemiology, Leading Companies And Therapies | DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s \u201cWet Age-related Macular Degeneration (wet AMD)  \u2013 Market Insights, Epidemiology, and Market Forecast-2030\u201d report delivers an in-depth understanding of the Wet Age-related Macular Degeneration (wet AMD) , historical and forecasted epidemiology as well as the  Wet Age-related Macular Degeneration (wet AMD)  market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.\n<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight has launched a new report on &#8220;<strong>Wet Age-related Macular Degeneration (wet AMD) -Market Insights, Epidemiology, and Market Forecast-2030<\/strong>&rdquo;.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&rsquo;s &ldquo;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/wet-age-related-macular-degeneration-wet-amd-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\"><strong>Wet Age-related Macular Degeneration (wet AMD)&nbsp; &ndash; Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/a>&rdquo; report delivers an in-depth understanding of the Wet Age-related Macular Degeneration (wet AMD) , historical and forecasted epidemiology as well as the&nbsp; Wet Age-related Macular Degeneration (wet AMD)&nbsp; market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the key facts of the Report:<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Age is an important factor in the progression of the disease. In 2020, there were&nbsp; 214,275 cases in the age group of 61&ndash;70 years, which was the highest in any age group in the USA. This was followed by 169,164 cases in the age group of 51&ndash;60. The cases will rise to 219,912 and 173,614 in the age group of 61&ndash;70 and 51&ndash;60 years, respectively, by 2030 in the USA.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">In 2020, Germany had the highest population of wet-AMD among the European countries with 563,881 cases, followed by Italy, which had 419,403 cases.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Among the EU5 countries, Spain had the lowest prevalent population with 300,552 cases in 2020.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The prevalent population of wet AMD in Japan comprised813,974 cases in 2020<\/p>\n<\/li>\n<\/ol>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Key benefits of the report:<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Wet Age-related Macular Degeneration (wet AMD) market report covers a descriptive overview and comprehensive insight of the Wet Age-related Macular Degeneration (wet AMD)&nbsp; epidemiology and Wet Age-related Macular Degeneration (wet AMD) market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) &amp; Japan.)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. The Wet Age-related Macular Degeneration (wet AMD) market report provides insights on the current and emerging therapies.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Wet Age-related Macular Degeneration (wet AMD) market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. The Wet Age-related Macular Degeneration (wet AMD) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Wet Age-related Macular Degeneration (wet AMD) market.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Request for sample pages:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/wet-age-related-macular-degeneration-wet-amd-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\"><span data-sheets-value=\"{\" data-sheets-userformat=\"{\">https:\/\/www.delveinsight.com\/sample-request\/wet-age-related-macular-degeneration-wet-amd-market<\/span><\/a><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/metabolic-acidosis-market\"><br \/><\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Wet Age-related Macular Degeneration (wet AMD) : Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Wet macular degeneration is a chronic eye disorder that causes blurred vision or a blind spot in your visual field. It&#8217;s generally caused by abnormal blood vessels that leak fluid or blood into the macula (MAK-u-luh). The macula is in the part of the retina responsible for central vision<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The key players involved in the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/wet-age-related-macular-degeneration-wet-amd-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\">Wet Age-related Macular Degeneration (wet AMD) market<\/a>:<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Roche<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Chengdu Kanghong Biotech<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Kodiak Sciences<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Opthea<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Regenxbio<\/p>\n<\/li>\n<\/ol>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The launch of the emerging therapies is expected to significantly impact the&nbsp; Wet Age-related Macular Degeneration (wet AMD)&nbsp; treatment scenario in the upcoming years:-<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Drug covered<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Faricimab<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Conbercept<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">KSI-301<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">OPT-302<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">RGX-314<\/p>\n<\/li>\n<\/ol>\n<p style=\"text-align: justify;\"><strong>Request a free sample report @<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/wet-age-related-macular-degeneration-wet-amd-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\"><span data-sheets-value=\"{\" data-sheets-userformat=\"{\">https:\/\/www.delveinsight.com\/sample-request\/wet-age-related-macular-degeneration-wet-amd-market<\/span><\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. SWOT analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Wet Age-related Macular Degeneration (wet AMD) Patient Share (%) Overview at a Glance<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Wet Age-related Macular Degeneration (wet AMD) Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Wet Age-related Macular Degeneration (wet AMD) Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Wet Age-related Macular Degeneration (wet AMD) Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Country-Specific Patient Population of Wet Age-related Macular Degeneration (wet AMD)&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Wet Age-related Macular Degeneration (wet AMD) Current Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Wet Age-related Macular Degeneration (wet AMD) Emerging Therapies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Wet Age-related Macular Degeneration (wet AMD) Market Outlook<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Country-Wise Wet Age-related Macular Degeneration (wet AMD) Market Analysis (2017&ndash;2030)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Market Access and Reimbursement of Therapies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Market drivers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Market barriers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Wet Age-related Macular Degeneration (wet AMD) Report Methodology<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Disclaimer<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. About DelveInsight<\/p>\n<p style=\"text-align: justify;\"><strong>Related Reports:<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Wet Age-related Macular Degeneration (wet AMD)- Pipeline Insights, 2021<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&#8220;Wet Age-related Macular Degeneration (wet AMD)- Pipeline Insight, 2021&#8221; report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Wet Age-related Macular Degeneration (wet AMD) market. A detailed picture of the Wet Age-related Macular Degeneration (wet AMD) pipeline landscape is provided, which includes the disease overview and Wet Age-related Macular Degeneration (wet AMD) treatment guidelines.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Wet Age-related Macular Degeneration (wet AMD) -Epidemiology Forecast to 2030<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s &#8216;Wet Age-related Macular Degeneration (wet AMD) &#8211; Epidemiology Forecast to 2030&#8217; report delivers an in-depth understanding of the disease, historical and forecasted Wet Age-related Macular Degeneration (wet AMD){;l epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=wet-agerelated-macular-degeneration-wet-amd-market-analysis-market-size-trends-epidemiology-leading-companies-and-therapies-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=wet-agerelated-macular-degeneration-wet-amd-market-analysis-market-size-trends-epidemiology-leading-companies-and-therapies-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight\u2019s \u201cWet Age-related Macular Degeneration (wet AMD) \u2013 Market Insights, Epidemiology, and Market Forecast-2030\u201d report delivers an in-depth understanding of the Wet Age-related Macular Degeneration (wet AMD) , historical and forecasted epidemiology as well as the &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/wet-agerelated-macular-degeneration-wet-amd-market-analysis-market-size-trends-epidemiology-leading-companies-and-therapies-delveinsight_544891.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-544891","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/544891","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=544891"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/544891\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=544891"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=544891"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=544891"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}